Agilent Technologies : Resolution ctDx FIRST Receives FDA Approval as a Liquid Biopsy Companion Diagnostic Test for Advanced Non-small Cell Lung Cancer

Agilent Technologies Inc. announced today that the U.S. Food and Drug Administration has approved Agilent Resolution ctDx FIRST as a companion diagnostic to identify advanced... | December 12, 2022

Related Keywords

United States ,American ,Alan Sandler ,Kenna Anderes ,Sam Raha ,Dacosta Byfield ,Agilent Technologies Inc ,Genomics Group ,Cancer Center ,Drug Administration ,American Cancer Society ,Agilent Technologies ,Agilent Resolution ,Vice President ,Translational Medicine ,Chief Medical ,Key Statistics ,American Cancer ,About Lung Cancer Web ,Retrospective Analysis ,Lung Cancer ,Clinicoecon Outcomes ,Somatic Mutations ,Patient Reported Preferences ,Liquid Biopsies ,Blood Biomarkers ,Comprehensive Cancer ,Cancer Manag Res ,Prospective Study ,Circulating Tumor ,Guide Matched Targeted Therapy ,Nc Stock Exchange ,News ,Information ,Press Release ,Agilent ,Technologies ,Nnounced ,Oday ,Hat ,The ,Wood ,End ,Drug ,Administration ,Gas ,Approved ,Resolution ,Ltdx ,First ,Us ,Companion ,Iagnostic ,O ,Dentifya Us00846u1016 ,